Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 13, 2014, Pages 4940-4945

  Cai, Weijing ^a   Uribarri, Jaime ^a   Zhu, Li ^a   Chen, Xue ^a   Swamy, Shobha ^a   Zhao, Zhengshan ^a   Grosjean, Fabrizio ^a   Simonaro, Calogera ^a   Kuchel, George A ^a   Schnaider Beeri, Michal ^b   Woodward, Mark ^c,d   Striker, Gary E ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d George Institute   (Australia)

Author keywords

Caloric restriction; Insulin resistance; Neural; Nutrition; Obesity

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 1; AMYLOID BETA PROTEIN[1-42]; INSULIN; METHYLGLYOXAL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIRTUIN 1; UNCLASSIFIED DRUG;

ADULT; AGING; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CHRONIC INFLAMMATION; CHRONIC STRESS; COGNITIVE DEFECT; CONTROLLED STUDY; EMBRYO; EPIDEMIC; FEMALE; GENE EXPRESSION; GLIOSIS; HOST RESISTANCE; HUMAN; INSULIN SENSITIVITY; LEARNING; MALE; MEMORY; METABOLIC SYNDROME X; MOUSE; NEOCORTEX; NONHUMAN; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; WILD TYPE;

CALORIC RESTRICTION; INSULIN RESISTANCE; NEURAL; NUTRITION; OBESITY;

ADAM PROTEINS; ADMINISTRATION, ORAL; AGED; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; COGNITION; CYTOKINES; DEMENTIA; FEMALE; GLIOSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; MALE; MEMBRANE PROTEINS; MEMORY; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATIVE STRESS; PPAR GAMMA; PYRUVALDEHYDE; RECEPTORS, IMMUNOLOGIC; SIRTUIN 1; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84897555551     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316013111     Document Type: Article

References (42)

1. Janson J, et al. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474-481.
2. Guarente L, Franklin H (2011) Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med 364(23):2235-2244.
3. Talbot K, et al. (2012) Demonstrated brain insulin resistance in Alzheimer?s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316-1338.
4. Reddy VP, Zhu X, Perry G, Smith MA (2009) Oxidative stress in diabetes and Alzheimer?s disease. J Alzheimers Dis 16(4):763-774.
5. Loy CT, Twigg SM (2009) Growth factors, AGEing, and the diabetes link in Alzheimer?s disease. J Alzheimers Dis 16(4):823-831.
6. Vlassara H, Striker GE (2011) AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 7(9):526-539.
7. Srivastava S, Haigis MC (2011) Role of sirtuins and calorie restriction in neuroprotection: Implications in Alzheimer?s and Parkinson?s diseases. Curr Pharm Des 17(31):3418-3433.
8. Qin W, et al. (2008) Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer?s disease-type amyloid neuropathology and spatial memory deterioration. Ann Acad Sci 1147:335-347.
9. Longo VD, Kennedy BK (2006) Sirtuins in aging and age-related disease. Cell 126(2): 257-268.
10. Bonda DJ, et al. (2011) The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lanceteurol 10(3):275-279.
11. Fusco S, et al. (2012) A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction. Procatl Acad Sci USA 109(2):621-626.
12. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE (2006) Diabetes and advanced glycoxidation end products. Diabetes Care 29(6):1420-1432.
13. Vitek MP, et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Procatl Acad Sci USA 91(11):4766-4770.
14. Zimmerman GA, et al. (1995)eurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Procatl Acad Sci USA 92(9):3744-3748.
15. Srikanth V, et al. (2013) Methylglyoxal, cognitive function and cerebral atrophy in older people. J Gerontol A Biol Sci Med Sci 68(1):68-73.
16. Li XH, et al. (2012) Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formationNeuromolecular Med 14(4):338-348.
17. Beeri MS, et al. (2011) Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev 132(11-12):583-587.
18. Ahmed N, et al. (2005) Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer?s disease and link to cognitive impairment. Jeurochem 92(2):255-263.
19. Koschinsky T, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Procatl Acad Sci USA 94(12): 6474-6479.
20. Birlouez-Aragon I, et al. (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 91(5):1220-1226.
21. Cai W, et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173(2):327-336.
22. Cai W, et al. (2012) Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Procatl Acad Sci USA 109(39):15888-15893.
23. Uribarri J, et al. (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: Potential role of AGER1 and SIRT1. Diabetes Care 34(7):1610-1616.
24. Uribarri J, et al. (2013) Suppression of native defense mechanisms, SIRT1 and PPAR?, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 46(2):301-309.
25. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell 142(2):320-332.
26. Vlassara H, et al. (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94(11):4483-4491.
27. Dickson DW, et al. (1996) Glycation and microglial reaction in lesions of Alzheimer?s diseaseNeurobiol Aging 17(5):733-743.
28. Schmidt AM, et al. (2009) The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer?s disease. Curr Opin Investig Drugs 10(7):672-680.
29. Ko SY, Li Yn P, Lin Y S, Chang SS (2010) Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49(3):474-480.
30. Li JJ, Dickson D, Hof PR, Vlassara H (1998) Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis. Mol Med 4(1):46-60.
31. Takuma K, et al. (2009) RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Procatl Acad Sci USA 106(47): 20021-20026.
32. Ford D, Ions LJ, Alatawi F, Wakeling LA (2011) The potential role of epigenetic responses to diet in ageing. Procutr Soc 70(3):374-384.
33. Marques SC, et al. (2012) Epigenetic regulation of BACE1 in Alzheimer?s disease patients and in transgenic mice Neuroscience 220:256-266.
34. Correia SC, et al. (2011) Insulin-resistant brain state: The culprit in sporadic Alzheimer?s disease? Ageing Res Rev 10(2):264-273.
35. Deane R, et al. (2012) A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122(4):1377-1392.
36. Mich?n S, et al. (2010) SIRT1 is essential for normal cognitive function and synaptic plasticity. Jeurosci 30(29):9695-9707.
37. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-?-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer?s disease. Jeurosci 32(30):10117-10128.
38. Monville C, Torres EM, Dunnett SB (2006) Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. Jeurosci Methods 158(2):219-223.
39. Barker GR, Bird F, Alexander V, Warburton EC (2007) Recognition memory for objects, place, and temporal order: A disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. Jeurosci 27(11):2948-2957.
40. Uribarri J, et al. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110(6):911-916, e12.
41. Bucala R, et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91(20):9441-9445.
42. Fu MX, et al. (1996) The advanced glycation end product,epsilon- (carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271(17):9982-9986.